Some of our recent news articles.
WUXI, China, June 21, 2019 –WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art integrated biologics conjugation solution center to include commercial manufacturing in Wuxi city, China.
This week, the FDA approved Trogarzo (ibalizumab-uiyk), the first HIV therapy with a novel mechanism of action in more than 10 years and the first drug developed by Taiwan-based TaiMed Biologics. It also represents a first for WuXi Biologics, the Chinese company that will produce it at a biologics plant near Shanghai.
Production of HIV drug Trogarzo is now approved at the Wuxi facility